Key result
The R203K/G204R mutations in the SARS-CoV-2 nucleocapsid protein were associated with a significant increase in viral load (adjusted mean increase of 0.57 log10 units) in COVID-19 patients.
Why the study?
Monitoring SARS-CoV-2 spread and evolution through genome sequencing and linking genomic sequence information to clinical records is essential in handling the COVID-19 pandemic.
Observational (n=892)
Yes
Mean Difference: 0.57 (95% CI 0.13–1.01)
The R203K/G204R mutations in the SARS-CoV-2 nucleocapsid protein modulate host-virus interactions and increase viral load, highlighting the N protein as a potential drug target.
Hypothesis-generating for nucleocapsid-targeted antivirals; leaves open clinical relevance of R203K/G204R mutations.
Summary Monitoring SARS-CoV-2 spread and evolution through genome sequencing is essential in handling the COVID-19 pandemic. The availability of patient hospital records is crucial for linking the genomic sequence information to virus function during the course of infections. Here, we sequenced 892 SARS-CoV-2 genomes collected from patients in Saudi Arabia from March to August 2020. From the assembled sequences, we estimate the SARS-CoV-2 effective population size and infection rate and outline the epidemiological dynamics of import and transmission events during this period in Saudi Arabia. We show that two consecutive mutations (R203K/G204R) in the SARS-CoV-2 nucleocapsid (N) protein are associated with higher viral loads in COVID-19 patients. Our comparative biochemical analysis reveals that the mutant N protein displays enhanced viral RNA binding and differential interaction with key host proteins. We found hyper-phosphorylation of the adjacent serine site (S206) in the mutant N protein by mass-spectrometry analysis. Furthermore, analysis of the host cell transcriptome suggests that the mutant N protein results in dysregulated interferon response genes. We provide crucial information in linking the R203K/G204R mutations in the N protein as a major modulator of host-virus interactions and increased viral load and underline the potential of the nucleocapsid protein as a drug target during infection.
No takes yet. Share an insight, caveat, or question.
Mourier et al. (2021) conducted an observational in COVID-19 (n=892). R203K/G204R mutations in the SARS-CoV-2 nucleocapsid (N) protein vs. Reference (Wuhan) SARS-CoV-2 genome without R203K/G204R mutations was evaluated on Viral load (log10 viral copy number) (MD 0.57 log10 units, 95% CI 0.13-1.01). The R203K/G204R mutations in the SARS-CoV-2 nucleocapsid protein were associated with a significant increase in viral load (adjusted mean increase of 0.57 log10 units) in COVID-19 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: